Comcast exec named COO of Amazon healthcare joint venture

Amy Baxter | | Health Exec | Management
Amazon logo

Photo by Anna Shvets via Pexels

The healthcare venture formed by Amazon, Berkshire Hathaway and JPMorgan Chase has named Jack Stoddard as its new COO, according to CNBC.

The venture, which was announced in Jan. 2018 and still does not have an official name, named its CEO, Atul Gawanade, in June.

Stoddard most recently served as general manager for digital health at Comcast. He also served on the founding team of a Comcast Ventures-based startup, Accolade, and was part of the executive team for Optum’s claims processing engine, CNBC reported. His first day was Sept. 4, according to CNBC.

“We are very pleased to welcome Jack Stoddard to our team. He will serve as the chief operating officer of the organization going forward," an Amazon spokesperson told CNBC.

The mission of the healthcare venture is to improve health benefits and costs for the combined 1.1 million employees across the three companies. However, specifics on the entity are still unknown.

The news comes the day after Amazon’s value topped $1 trillion, marking the second U.S. business to reach that milestone. Apple achieved the value on Aug. 2.

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.